Large B Cell Lymphoma Lbcl clinical trials

Explore recruiting large b cell lymphoma lbcl clinical trials.

Recruiting large b cell lymphoma lbcl studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Large B Cell Lymphoma Lbcl trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Spain, France, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL).

Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With Fludarabine, Cyclophosphamide, And ALLO-647, Vs. Fludarabine And Cyclophosphamide Alone, In Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL) Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Belgium, Germany, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label, Multi-Center, Phase Ib/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

Italy, Belgium, Denmark, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An Open-Label, Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, a CD19 Targeted 4-1BB Ligand) in Combination with Obinutuzumab and in Combination with Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

Spain, Denmark, Belgium, Italy, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)

Austria, Italy, Germany, France, Netherlands, Portugal +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Large B Cell Lymphoma Lbcl trials by city

Large B Cell Lymphoma Lbcl in Toronto Large B Cell Lymphoma Lbcl in Vancouver Large B Cell Lymphoma Lbcl in Montreal Large B Cell Lymphoma Lbcl in Calgary Large B Cell Lymphoma Lbcl in Edmonton Large B Cell Lymphoma Lbcl in Ottawa Large B Cell Lymphoma Lbcl in Winnipeg Large B Cell Lymphoma Lbcl in Quebec City Large B Cell Lymphoma Lbcl in Hamilton Large B Cell Lymphoma Lbcl in Kitchener Large B Cell Lymphoma Lbcl in London Large B Cell Lymphoma Lbcl in Halifax Large B Cell Lymphoma Lbcl in New York Large B Cell Lymphoma Lbcl in Los Angeles Large B Cell Lymphoma Lbcl in Chicago Large B Cell Lymphoma Lbcl in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease